# Zetagen Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zetagen-therapeutics

- Industry: Biotechnology
- Headquarters: Syracuse, US
- Website: www.zetagen.com
- Total disclosed funding: $13M
- Latest round: Series B (Oct 31, 2025)
- Investors on record: 3

## About

Founded in 2015 and based in New York, US, Zetagen Therapeutics, In October 2025, Zetagen Therapeutics, Inc. operates as a clinical-stage, biopharmaceutical company. In October 2025, Zetagen Therapeutics, Inc. raised USD 12.82 million in series B funding led by  JStar Capital Investments. The round was part of larger USD 12.9 million in series B funding. The series B funding values Zetagen Therapeutics, Inc. at USD 158.88 million post-money.

The firm develops and offers biopharmaceuticals that are designed for intra-tumoral injection in soft tissue organs like the liver, lung, and or brain to help treat metastatic cancers to bone and other organs. The firm’s products include ZetaMet Flowable™, ZetaFuse™, ZetaSet™,  ZetaDent™, and ZetaBase™, which are designed to suspend cancer, inhibit pain, and regenerate bone. 

The company plans to use the October 2025 funding to advance its platform toward commercialization, accelerate clinical development, and complete its preclinical studies and GMP manufacturing.

## Funding rounds

- Series B, Oct 31, 2025, $13M — jStar Capital Investments
- Series B, Jan 21, 2025, $0.1M — New York Ventures, Consolidated Capital Investments

## Investors

- New York Ventures (https://capitalatlas.ai/funds/new-york-ventures) — Series B
- Consolidated Capital Investments — Series B
- jStar Capital Investments (https://capitalatlas.ai/funds/jstar-capital-investments) — Series B